MiR-30a upregulates BCL2A1, IER3 and cyclin D2 expression by targeting FOXL2

  • Authors:
    • Tairen Wang
    • Fei Li
    • Shengjian Tang
  • View Affiliations

  • Published online on: November 20, 2014     https://doi.org/10.3892/ol.2014.2723
  • Pages: 967-971
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

FOXL2 is a transcription factor that is essential for ovarian development. Somatic mutations of FOXL2 are associated with ovarian granulosa cell tumorigenesis. In the present study, the expression of FOXL2 was suppressed by microRNAs using the Ago2 knockdown method in COV434 cells. Online bioinformatics tools were utilized to predict that FOXL2 expression may be repressed by miR‑30 family members, and dual luciferase assay and western blotting were performed to demonstrate that FOXL2 is a target gene of miR‑30a, which is relatively abundant in COV434 cells. Furthermore, miR‑30a overexpression upregulates BCL2A1, IER3 and cyclin D2 expression by inhibiting FOXL2. miR‑30a is known to function as a tumor suppressor in breast cancer, small cell lung cancer and colorectal carcinoma; however, the present study revealed an opposing function of miR‑30a as an oncogene.
View Figures
View References

Related Articles

Journal Cover

February-2015
Volume 9 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang T, Li F and Tang S: MiR-30a upregulates BCL2A1, IER3 and cyclin D2 expression by targeting FOXL2. Oncol Lett 9: 967-971, 2015
APA
Wang, T., Li, F., & Tang, S. (2015). MiR-30a upregulates BCL2A1, IER3 and cyclin D2 expression by targeting FOXL2. Oncology Letters, 9, 967-971. https://doi.org/10.3892/ol.2014.2723
MLA
Wang, T., Li, F., Tang, S."MiR-30a upregulates BCL2A1, IER3 and cyclin D2 expression by targeting FOXL2". Oncology Letters 9.2 (2015): 967-971.
Chicago
Wang, T., Li, F., Tang, S."MiR-30a upregulates BCL2A1, IER3 and cyclin D2 expression by targeting FOXL2". Oncology Letters 9, no. 2 (2015): 967-971. https://doi.org/10.3892/ol.2014.2723